ADRB2 and Down syndrome: Conversely, other studies have reported that administration of a β2-AR antagonist exacerbates neuropathology and cognitive deficits in a mouse model of AD (65) and that pharmacological stimulation of β2-AR improves cognitive function and restores synaptic density in a mouse model of Down syndrome (66).